Covidien is buying ingestible-camera company Given Imaging.
The company says Docnet is more than a social site—it's a hub that merges networking, research and financial (as in Sunshine) resources.
The retraction comes six months after researchers were fired over misrepresented data.
The government division is scrutinizing marketing information for three drugs.
Reports of a Dec. 5 deal between the US and China could deepen inspectors' reach.
The drug is priced at $28,000 a month, before add-ons like ribivarin and (possibly) interferon.
Their letter to CMS voices disagreement with the decision to make textbooks and journals reportable under the Sunshine Act.
A survey of US hepatologists signals pent-up demand exists for the paradigm-changing HCV treatment, but that not all patients will get the drug right away.
The drug failed to hit its Phase III targets.
Phase-IIIb study results indicate Lyxumia—which is approved abroad but not in the US—was "non-inferior" in terms of controlling blood sugar levels regardless of whether the shot was given before breakfast or later.